Verrica Pharmaceuticals Inc. (VRCA)
VRCA Stock Price Chart
Explore Verrica Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze VRCA price movements and trends.
VRCA Company Profile
Discover essential business fundamentals and corporate details for Verrica Pharmaceuticals Inc. (VRCA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Jun 2018
Employees
76.00
Website
https://www.verrica.comCEO
Jayson Rieger
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA Financial Timeline
Browse a chronological timeline of Verrica Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.40, while revenue estimate is $5.90m.
Earnings released on 12 May 2026
EPS came in at -$0.41 surpassing the estimated -$0.59 by +30.51%, while revenue for the quarter reached $5.02m , beating expectations by +11.27%.
Earnings released on 11 Mar 2026
EPS came in at -$0.56 falling short of the estimated -$0.43 by -30.23%, while revenue for the quarter reached $5.09m , beating expectations by +12.65%.
Earnings released on 14 Nov 2025
EPS came in at $0.13 surpassing the estimated -$1.14 by +111.40%, while revenue for the quarter reached $14.34m , beating expectations by +217.35%.
Earnings released on 12 Aug 2025
EPS came in at $0.02 surpassing the estimated -$0.70 by +102.86%, while revenue for the quarter reached $12.70m , beating expectations by +96.93%.
Stock split effective on 25 Jul 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2025
EPS came in at -$1.00 surpassing the estimated -$1.40 by +28.57%, while revenue for the quarter reached $3.44m , missing expectations by -2.65%.
Earnings released on 11 Mar 2025
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $344.00k , missing expectations by -83.69%.
Earnings released on 4 Nov 2024
EPS came in at -$0.49 falling short of the estimated -$0.37 by -32.43%, while revenue for the quarter reached -$1.78m , missing expectations by -436.04%.
Earnings released on 14 Aug 2024
EPS came in at -$0.31 surpassing the estimated -$0.43 by +27.91%, while revenue for the quarter reached $5.18m , beating expectations by +18.47%.
Earnings released on 13 May 2024
EPS came in at -$0.38 surpassing the estimated -$0.54 by +29.63%, while revenue for the quarter reached $3.83m , beating expectations by +37.63%.
Earnings released on 29 Feb 2024
EPS came in at -$0.48 falling short of the estimated -$0.47 by -2.13%, while revenue for the quarter reached $1.99m , beating expectations by +118.46%.
Earnings released on 9 Nov 2023
EPS came in at -$0.32 falling short of the estimated -$0.22 by -45.45%, while revenue for the quarter reached $2.92m , beating expectations by +471.96%.
Earnings released on 8 Aug 2023
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%, while revenue for the quarter reached $182.00k , beating expectations by +160.00%.
Earnings released on 9 May 2023
EPS came in at -$0.13 surpassing the estimated -$0.20 by +35.00%, while revenue for the quarter reached $37.00k , missing expectations by -91.40%.
Earnings released on 6 Mar 2023
EPS came in at -$0.11 surpassing the estimated -$0.20 by +45.00%, while revenue for the quarter reached $68.00k , missing expectations by -78.24%.
Earnings released on 7 Nov 2022
EPS came in at $0.07 surpassing the estimated -$0.11 by +163.64%, while revenue for the quarter reached $8.32m , beating expectations by +92.14%.
Earnings released on 11 Aug 2022
EPS came in at -$0.32 matching the estimated -$0.32, while revenue for the quarter reached $214.00k , missing expectations by -31.52%.
Earnings released on 9 May 2022
EPS came in at -$0.25 surpassing the estimated -$0.54 by +53.70%, while revenue for the quarter reached $431.00k , beating expectations by +29.66%.
Earnings released on 2 Mar 2022
EPS came in at -$0.35 surpassing the estimated -$0.48 by +27.08%, while revenue for the quarter reached -$12.00m , missing expectations by -4.72k%.
Earnings released on 12 Nov 2021
EPS came in at -$0.40 surpassing the estimated -$0.49 by +18.37%.
Earnings released on 10 Aug 2021
EPS came in at -$0.35 surpassing the estimated -$0.41 by +14.63%.
VRCA Stock Performance
Access detailed VRCA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
